翻译尚未完成，当前显示原文。
Key PointsArgenx’s Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
